At least the S-1 apparently gives individual shareholders the right to buy into any future stock offering without any warrants attached. I hope a positive 12-month PR doubles the stock price before pricing of an offering.
I was very disappointed to see STEM's S-1 filing. Major companies should be lining up to partner with STEM in a future market potentially worth billions. Another example of self serving management.
STEM, please do not take the foolish path of many microcaps in trying to go it alone. Get a partnership NOW with ample upfront money and the partner paying all future costs. If you have to, make it a 50/50 split. Shareholders will be richly rewarded.
With a prominent partner and positive study results in late 2017, the FDA could forgo a phase 3 study and invite STEM to file for approval. The lobby for paralyzed Americans is large and influential.
The market is asleep as to STEM's potential. At a past conference management indicated that stem cell injections are active for at least six years. Why does the market expect an overnight cure when gradual ongoing regain of muscle function is big news? Athletes often have surgeries that sideline them a year or two and that is accepted. Years ago I had detached retina surgery in Chicago. The first operation was unsuccessful, the second one did not appear to be successful. The day before I was to leave for a retina clinic in Boston, my body decided it was time to work its magic. My retina was detached for four months, but I did regain useful sight in the affected eye.
The six patients had older injuries, yet still improved and may for years to come. The new patients coming into the study will hopefully include ones with more recent injuries and be better candidates.
If stem cells can help the patient profiled on CBS, who had his injury April 2013, think what can happen with a recent injury patient injected with stem cells. It is not surprising that sensation in Jason's lower extremities is showing more gradual improvement: the feet get the least amount of blood supply.
There is a high probability that most of the patients will show continued gains between 6 and 12 months. The stem cells are waking up the body's healing process. These patients are young and better able to improve. I had a friend in his late 60s who had a foot drop from a spinal injury. He thought he would never recover, but he did-fully, in his early 70s. Youth may be wasted on the young, but not in spinal injuries.
The amazing thing is the patients had injuries years back. In the future stem cells may be injected within months or even weeks of a spinal cord injury.
With decent 12-month data STEM could explode like CLRB today. STEM volume is modest today, partly due to shorts not wanting to cover en masse and run up the price. Better than expected data next week could cause a short squeeze.
Stem cell therapy needs to show superiority to standard of care physical therapy. PT has advanced quite a bit in the last 20 years and has enabled quite a few patients to gain partial motor function. Stem cell therapy has to at least show that it can clearly augment and accelerate PT.
You can go to E-Trade ad confirm what I reported. It's in the record. The sales figure for 2019 assumes great PATHWAY results and an explosion in stem cell patients.
All previous years' sales are negligible.
Here it is the 16th and no announced 1st qtr date. 2015 was done on May 5; 2014 on May 14: 2013 on May 9: 2012 on May 10.
Today's aggressive beat down on moderate volume could be shaking out weak hands as Barrons still shows STEM under accumulation.
Very weird trading today, yet Barrons still showing STEM under accumulation. Anyone can check for free at Barrons site, updated every 15 minutes.
Despite the bear raid today on relatively modest volume, Barrons actually shows the stock under ACCUMULATION. Regarding Pfizer, I owned Encysive in 2007-08: It crashed from $7.10 to $.59 and was bought by PFE for $2.35 plus paying off a whopping $140 million debt. Did you notice when you went to STEM's Yahoo summary page there was a pop up to the ongoing PATHWAY study?
andy: If you view the newspaper and TV segments publicized by STEM, you will see that profiled patients do reveal quite a bit about their progress. Just as shadowy figures monitor star athletes as early as junior high, a deep pocket hedge fund could easily hire spies to shadow self-identified patients. Insurance companies do this all the time, filming "disabled" claimants filing fraudulent claims.
My CONS: 1) If results were outstanding STEM would have issued an immediate PR instead of waiting for the quarterly CC; 2) some of the participants, identified in news stories, have undoubtedly been contacted by big players. Why has not the stock price jumped big?
PROS: 1) STEM has promised to present the data at a June conference; one rarely does this for truly bad results; 2) STEM may be letting potential partners see the data first. This is permissible if the likes of Merck or Pfizer sign confidentiality agreements.
According to STEM's website they have licensed their technology to heavyweights Merck and Pfizer. STEM is ripe for a big deal.
I got back into STEM on Wednesday: 850 shares @ 3.38. The tiny float and market cap are ultra appealing. Look what happened with DNDN, a company with a marginal drug: went as high as $5B market cap before it flamed out. With just modest results STEM can be a $1B stock. If even a few patients can walk again, $10B market cap is possible.